- Home
- BOLT vs INM Comparison
BOLT vs INM Comparison
Compare BOLT & INM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BOLT | INM |
|---|---|---|
| Founded | 2015 | 1981 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.1M | 7.1M |
| IPO Year | 2021 | 2020 |
Fundamental Metrics
Financial Performance| Metric | BOLT | INM |
|---|---|---|
| Price | $3.67 | $1.32 |
| Analyst Decision | Buy | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $29.00 | N/A |
| AVG Volume (30 Days) | 31.2K | ★ 52.7K |
| Earning Date | 11-11-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 62.68 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $7,695,000.00 | $4,942,633.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $2,525.07 | $26.00 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | 0.07 | ★ 7.50 |
| 52 Week Low | $3.10 | $0.58 |
| 52 Week High | $7.20 | $2.50 |
Technical Indicators
Market Signals| Indicator | BOLT | INM |
|---|---|---|
| Relative Strength Index (RSI) | 47.24 | 44.37 |
| Support Level | $3.13 | $1.25 |
| Resistance Level | $4.34 | $1.40 |
| Average True Range (ATR) | 0.32 | 0.06 |
| MACD | -0.00 | 0.01 |
| Stochastic Oscillator | 40.48 | 35.28 |
Price Performance
Historical ComparisonAbout BOLT Bolt Biotherapeutics Inc.
Bolt Biotherapeutics Inc is a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer. The company is focused on the clinical development of BDC-4182, its claudin 18.2 ISAC. Its other pipeline programs include CEA ISAC program a Boltbody ISAC targeting carcinoembryonic antigen cell adhesion molecule 5, or CEA; PD-L1 ISAC utilizes a novel human anti-PD-L1 antibody conjugated to a next-generation TLR7/8 agonist payload via a non-cleavable linker; and BDC-3042, its dectin-2 agonist antibody program, developed to repolarize critical cells in the tumor microenvironment known as tumor associated macrophages. It operates in single segment.
About INM InMed Pharmaceuticals Inc.
InMed Pharmaceuticals Inc is a pharmaceutical company developing a pipeline of disease-modifying small molecule drug candidates targeting CB1 and CB2 receptors. The company's pipeline consists of three separate programs in the treatment of Alzheimer's, ocular and dermatological indications.